GHD Stock Overview A biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. More details
Rewards Risk Analysis + 3 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Brainstorm Cell Therapeutics Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Brainstorm Cell Therapeutics Historical stock prices Current Share Price US$2.69 52 Week High US$12.03 52 Week Low US$2.69 Beta 0.35 1 Month Change 0% 3 Month Change -17.99% 1 Year Change -22.09% 3 Year Change -94.82% 5 Year Change -95.10% Change since IPO -97.61%
Recent News & Updates
Brainstorm Cell Therapeutics Inc. Strengthens Exosome Patent Portfolio; Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology Dec 04
Brainstorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement Oct 30 Brainstorm Cell Therapeutics Implements 1-for-15 Reverse Stock Split to Meet Nasdaq's Minimum Bid Price Requirement Oct 02
Brainstorm Cell Therapeutics Inc., Annual General Meeting, Sep 16, 2024 Aug 01
Brainstorm Cell Therapeutics Receives Deficiency Notice from Nasdaq Due to Non-Compliance with the Minimum of $35 Million Market Value of Listed Securities Pursuant to Nasdaq Listing Rule 5550(b)(2) Jul 20 Brainstorm Cell Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $4 million. Jun 28
See more updates
Brainstorm Cell Therapeutics Inc. Strengthens Exosome Patent Portfolio; Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology Dec 04
Brainstorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement Oct 30 Brainstorm Cell Therapeutics Implements 1-for-15 Reverse Stock Split to Meet Nasdaq's Minimum Bid Price Requirement Oct 02
Brainstorm Cell Therapeutics Inc., Annual General Meeting, Sep 16, 2024 Aug 01
Brainstorm Cell Therapeutics Receives Deficiency Notice from Nasdaq Due to Non-Compliance with the Minimum of $35 Million Market Value of Listed Securities Pursuant to Nasdaq Listing Rule 5550(b)(2) Jul 20 Brainstorm Cell Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $4 million. Jun 28
Brainstorm Cell Therapeutics Inc. Reaches Alignment with Fda on Cmc Aspects of Phase 3B Nurown®? Clinical Trial Jun 26
New major risk - Revenue and earnings growth Jun 21
Brainstorm Cell Therapeutics Announces Appointment of Haro Hartounian as EVP and COO Jun 20
Brainstorm Cell Therapeutics Inc. Announces Non-Compliance Update Jun 05
Brainstorm Cell Therapeutics Receives Staff Determination Letter from Nasdaq Regarding it Not Regains Compliance with the Minimum Bid Price Requirement by April 29, 2024 and Submits a Hearing Request to the Nasdaq Hearings Panel to Appeal the Staff’s Determination May 04 Brainstorm Cell Therapeutics Inc. Announces Management Changes
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule Apr 12
BrainStorm Cell Therapeutics Inc. Announces Agreement with FDA on Special Protocol Assessment for Phase 3b Trial in ALS Apr 09
New major risk - Shareholder dilution Apr 08
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn in ALS Feb 23
Brainstorm Cell Therapeutics Inc. Announces Executive Changes Dec 21
BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS Dec 08
Brainstorm Cell Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance Market Value of Listed Securities Requirement for Continued Listing on The Nasdaq Capital Market Nov 11
Brainstorm Cell Therapeutics Inc., Annual General Meeting, Dec 18, 2023 Nov 09
Brainstorm Cell Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2) Nov 06 Brainstorm Cell Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2) Nov 05
Brainstorm Cell Therapeutics Receives Non-Compliance Notice from Nasdaq
Gainey Mckenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc Nov 03 BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn for the Treatment of ALS
New minor risk - Profitability Oct 24
Brainstorm Cell Therapeutics Inc. to Report Q2, 2023 Results on Aug 14, 2023 Aug 09
BrainStorm Cell Therapeutics Inc. Appoints Bob Dagher as Executive Vice President and Chief Development Officer Jul 13
Brainstorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair Jun 22
New minor risk - Market cap size Jun 21
Forecast to breakeven in 2025 May 26
Brainstorm Cell Therapeutics Inc Announces Resignation of David Setboun as Executive Vice President and Chief Operating Officer May 26
Forecast to breakeven in 2025 Apr 06
No longer forecast to breakeven Mar 30
BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer Jan 05
Brainstorm Cell Therapeutics Inc. Announces Type A Meeting with FDA Granted for NurOwn® Dec 28
Brainstorm Cell Therapeutics Inc., Annual General Meeting, Jan 10, 2023 Dec 14
BrainStorm Cell Therapeutics Submits Type A Meeting Request to U.S. Food and Drug Administration Dec 13
Brainstorm Cell Therapeutics Seeks FDA Approval of Mesenchymal Stem Cell Therapy Called NurOwn for the Treatment of ALS Nov 22
Brainstorm Cell Therapeutics Inc. Receives Refusal to File Letter from FA for Its New Biologics License Application for Nurown for the Treatment of Als Nov 11
BrainStorm Presents New Biomarker Analyses from NurOwn's Phase 3 ALS Trial at the ALS ONE Research Symposium Oct 08
Brainstorm Cell Therapeutics Inc. Announces Peer Reviewed Publication of Results from the Nurown Phase 2 Progressive MS Trial in Multiple Sclerosis Journal Sep 16
Brainstorm Cell Therapeutics Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for NurOwn for the Treatment of Amyotrophic Lateral Sclerosis Aug 16
Brainstorm Cell Therapeutics Inc. Appoints Antal Pearl-Lendner as Chief Legal Counsel May 13
BrainStorm Cell Therapeutics Inc. Announces Presentation of Nurown® Exosome Preclinical Data At ISCT 2022 San Francisco Meeting May 05
U.S. Food and Drug Administration Authorizes Further Brainstorm Cell Therapeutics Inc.'s Nurown Dosing Under Expanded Access Program Dec 28
Brainstorm Cell Therapeutics Announces Peer Reviewed Publication of Nurown's® Phase 3 Study for Als in Muscle and Nerve Dec 14
BrainStorm Cell Therapeutics Announces the Presentation of New Analyses from the Phase 3 Trial of NurOwn® in ALS at the 4th Annual ALS ONE Research Symposium Nov 30
No longer forecast to breakeven Aug 07 Brainstorm Cell Therapeutics Inc.(NasdaqCM:BCLI) dropped from Russell 3000 Growth Index
New 90-day low: €3.28 Feb 25
Brainstorm Cell Therapeutics Inc. Announces High-Level FDA Feedback on NurOwn® ALS Clinical Development Program Feb 23
Brainstorm Cell Therapeutics Inc. Announces Feedback from FDA Type-C Meeting on Future NurOwn® Manufacturing Plan Feb 10
Brainstorm Cell Therapeutics Inc. to Report Q4, 2020 Results on Feb 04, 2021 Jan 29
BrainStorm Announces the Publication of Preclinical Data Highlighting the Potential of a NurOwn® Derived Exosome-Based Treatment for COVID-19 ARDS Jan 22
Brainstorm Cell Therapeutics Inc. Announces Completion of All Dosing in NurOwn® Phase 2 MS Study Dec 20
BrainStorm Announces NurOwn® Expanded Access Program Dec 15
New 90-day low: €3.42 Nov 19
BrainStorm Cell Therapeutics Inc. Announces Topline Results from NurOwn® Phase 3 ALS Study Nov 18
New 90-day high: €14.80 Oct 08
Brainstorm Cell Therapeutics Inc. Appoints William K. White as Senior Vice President, Head of Market Access & Pricing Sep 30
Brainstorm Cell Therapeutics Inc. to Report Q2, 2020 Results on Aug 03, 2020 Jul 31 Shareholder Returns GHD DE Biotechs DE Market 7D 0% 2.1% -0.1% 1Y -22.1% -9.7% 7.4%
See full shareholder returns
Return vs Market: GHD underperformed the German Market which returned 7.2% over the past year.
Price Volatility Is GHD's price volatile compared to industry and market? GHD volatility GHD Average Weekly Movement n/a Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: GHD's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine GHD's volatility change over the past year.
About the Company Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases.
Show more Brainstorm Cell Therapeutics Inc. Fundamentals Summary How do Brainstorm Cell Therapeutics's earnings and revenue compare to its market cap? GHD fundamental statistics Market cap €13.40m Earnings (TTM ) -€13.65m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) GHD income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$14.23m Earnings -US$14.23m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/28 23:00 End of Day Share Price 2024/09/30 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Brainstorm Cell Therapeutics Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution null null ACF Equity Research Limited Jason Kolbert H.C. Wainwright & Co. Jason McCarthy Maxim Group
Show 1 more analysts 
